Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 15Gemcitabine 14durvalumab 9pembrolizumab 7Oxaliplatin 6Bevacizumab 6Capecitabine 5lenvatinib 4S 1 (combination) 3Liquid Biopsy 3Irinotecan 3Folfox protocol 3Fluorouracil 3Carboplatin 3zanidatamab 2tremelimumab 2envafolimab 2Trastuzumab 2Nivolumab 2Leucovorin 2Injections 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1toripalimab 1tislelizumab 1poly ICLC 1niraparib 1neratinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × Peptides × 90 days × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡